Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Kwai Han | - |
dc.contributor.author | Kim, Hyeoung-Joon | - |
dc.contributor.author | Min, Yoo Hong | - |
dc.contributor.author | Hong, Dae-Sik | - |
dc.contributor.author | Lee, Won Sik | - |
dc.contributor.author | Kim, Hee-Je | - |
dc.contributor.author | Shin, Ho-Jin | - |
dc.contributor.author | Park, Yong | - |
dc.contributor.author | Lee, Je-Hwan | - |
dc.contributor.author | Kim, Hawk | - |
dc.date.accessioned | 2021-07-19T02:41:01Z | - |
dc.date.available | 2021-07-19T02:41:01Z | - |
dc.date.created | 2021-05-20 | - |
dc.date.issued | 2021-05-07 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/81712 | - |
dc.description.abstract | Objective The clinical characteristics and therapeutic strategy in acute myeloid leukemia (AML) are influenced by patients' age. We evaluated the impact of age on remission induction therapy for AML. Methods We retrospectively analyzed 3,011 adult AML patients identified from a nationwide database between January 2007 and December 2011. Results Three hundred twenty-nine (10.9%) acute promyelocytic leukemia (APL) and 2,682 (89.1%) non-APL patients were analyzed. The median age was 51 years and 55% of patients were male. Six hundred twenty-three patients (21%) were at favorable risk, 1522 (51%) were at intermediate risk, and 743 (25%) were at poor risk. As the age increased, the proportion of those at favorable risk and who received induction chemotherapy decreased. After induction therapy, complete response (CR) was achieved in 81.5% (243/298) of APL and 62.4% (1,409/2,258) of non-APL patients; these rates decreased as the age increased, with an obvious decrement in those older than 60 years. The median overall survival of non-APL patients was 18.7 months, while that of APL patients was not reached, with a 75% five-year survival rate. Conclusions Age impacts both the biology and clinical outcomes of AML patients. Further studies should confirm the role of induction remission chemotherapy by age group. Copyright: © 2021 Yoo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLoS ONE | - |
dc.title | Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000665471900028 | - |
dc.identifier.doi | 10.1371/journal.pone.0251011 | - |
dc.identifier.bibliographicCitation | PLoS ONE, v.16, no.5 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85105441936 | - |
dc.citation.title | PLoS ONE | - |
dc.citation.volume | 16 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Yoo, Kwai Han | - |
dc.contributor.affiliatedAuthor | Kim, Hawk | - |
dc.type.docType | Article | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.